2013
PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD
Ghosh A, Holland A, Dogan Y, Yim N, Rao U, Young L, West M, Singer N, Lee H, Na I, Tsai J, Jenq R, Penack O, Hanash A, Lezcano C, Murphy G, Liu C, Sadelain M, Sauer M, Sant'Angelo D, van den Brink M. PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD. Cancer Research 2013, 73: 4687-4696. PMID: 23733752, PMCID: PMC3732814, DOI: 10.1158/0008-5472.can-12-4699.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsBone Marrow TransplantationFlow CytometryGraft vs Host DiseaseGraft vs Tumor EffectKruppel-Like Transcription FactorsLymphocyte ActivationLymphocyte Culture Test, MixedMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalPromyelocytic Leukemia Zinc Finger ProteinT-LymphocytesTransplantation, HomologousConceptsDonor T cellsT cellsPromyelocytic leukemia zinc fingerGVT effectInvariant natural killer T (iNKT) cellsAlloreactive donor T cellsAllogeneic bone marrow transplantationNatural killer T cellsTranscription factor promyelocytic leukemia zinc fingerKiller T cellsAlloreactive T cellsBone marrow transplantationConventional T cellsOverall improved outcomesLess GVHDLower GVHDPreserves graftTumor effectImproved survivalMarrow transplantationCytokine responsesImproved outcomesTumor relapseEffector functionsGVHD
2011
Cross-Presentation by Host CD8α+dendritic Cells Augments Graft-Versus-Tumor Effect without Aggravating Graft-Versus-Host Disease After Allogeneic BMT
Toubai T, Sun Y, Tawara I, Liu C, Reddy P. Cross-Presentation by Host CD8α+dendritic Cells Augments Graft-Versus-Tumor Effect without Aggravating Graft-Versus-Host Disease After Allogeneic BMT. Blood 2011, 118: 310. DOI: 10.1182/blood.v118.21.310.310.Peer-Reviewed Original ResearchAntigen presenting cellsTumor-specific antigensProfessional antigen presenting cellsGVT responseAllogeneic animalsGraft-VersusSyngeneic B6APC subsetsTumor cellsPoly IToll-like receptor 3Induction of GVHDGVHD target organsWild-type B6Acute GVHDAllo-BMTCD8α- DCsAllogeneic BMTGVHD modelGVHD severityGVT effectHost diseaseTumor effectTLR-3Allo-antigenInterleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation
Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun Y, Lowler K, Malter C, Nishimoto N, Hill G, Reddy P. Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clinical Cancer Research 2011, 17: 77-88. PMID: 21047980, PMCID: PMC3058832, DOI: 10.1158/1078-0432.ccr-10-1198.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationBone marrow transplantationDonor T cellsIL-6 deficiencyInterleukin-6MR16-1T cellsMarrow transplantationExperimental allogeneic bone marrow transplantationDonor regulatory T cellsBeneficial GVT effectsMR16-1 treatmentRegulatory T cellsProlongation of survivalDonor bone marrowEffector cell expansionRelevant murine modelIL-6 receptorBMT patientsGVT responseGVT effectHost diseaseBMT recipientsMAb therapyTumor effect